The evidence can say that pigment darkens and that serious harms have been reported. It cannot say how often anything happens, in whom, at what exposure, or for how long, because no controlled trial of cosmetic use exists. What is published is case reports, small series, systematic reviews of those reports, and chemical analyses of purchased vials.
Start with what type of study would answer the question
A photo sequence is an anecdote with an image attached. To support a claim about a product, an experiment needs a comparison group, a defined and verified exposure, prespecified outcomes, and follow-up long enough to catch what matters. For a tanning agent the meaningful outcomes would include pigment change measured instrumentally, adverse events, and skin lesion surveillance over years. Nothing in the melanotan II literature meets that description, and there is no registered program that would produce it, because the substance has no sponsor and no legal route to market.
The systematic review closest to the topic assessed self-tanning agents broadly, covering dihydroxyacetone, melanotan, forskolin and carotenoids across 68 peer-reviewed studies. Its finding on melanotan was not an efficacy estimate. It was that unregulated melanotan I and II use has produced serious adverse effects.
What the harm literature consists of
Case reports sit at the bottom of the evidence hierarchy for establishing causation and near the top for generating early warnings. Here they are numerous enough and consistent enough that regulators quote them. FDA’s published summary of potential significant safety risks for this substance names melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism, all drawn from published reports.
The individual reports give the texture. One describes a man who developed diffuse aching, sweating, tachycardia, mydriasis and tremor within hours of a subcutaneous injection of internet-purchased material, with creatine kinase climbing to nearly 18,000 international units per liter and intensive care admission for rhabdomyolysis. Another reports renal infarction with a review of the earlier kidney injury literature attached. Dermatology journals hold several melanoma reports, including melanoma in situ associated with melanotan use, and a recent case describing five primary melanomas in situ in a patient whose history included tanning bed use, melanotan exposure and anabolic hormone use.
What can and cannot be concluded
| Claim | Best available evidence | What that evidence can support |
|---|---|---|
| Skin darkens after use | Case reports, user photographs, receptor pharmacology | That the effect occurs. Not its size, duration, or consistency across people |
| It works on a predictable schedule | None | Nothing. No validated timeline has been established for cosmetic use |
| Moles darken and new ones appear | Multiple case reports plus the pharmacologic effect stated on the approved analogue’s label | That the effect is expected biology rather than a rare fluke. Not the rate in unsupervised users |
| It causes melanoma | Case reports of melanoma diagnosed during or after use | Temporal association and a plausible mechanism. Not causation and not risk magnitude |
| Systemic toxicity occurs | Individual reports of rhabdomyolysis, renal infarction and priapism | That severe events happen. Not how often, and not at what exposure |
| Products contain what is claimed | Analytical chemistry on purchased vials | Directly refutes the claim. Measured content and purity diverged substantially from listings |
| It protects against sun damage | None in humans for this compound | Nothing. Reported use frequently accompanies sunbed exposure |
Why absence of trials is not neutral here
For an approved drug, the absence of a specific trial usually means a question has not been prioritized. For an unapproved substance sold outside any regulatory system, the absence means nobody has ever been obliged to look. Adverse events are not collected systematically, so the published cases represent only those that reached a hospital, were recognized as connected to the exposure, and were written up. That is a small and unrepresentative fraction of whatever the true experience is, and the direction of that bias is toward understating harm rather than overstating it.
The comparison worth making is with the approved product in the same receptor class. Afamelanotide reached the market through three randomized, vehicle controlled trials in 244 adults with erythropoietic protoporphyria, and its label reports adverse reaction rates from that dataset, including nausea at 19 percent against 14 percent on vehicle and melanocytic nevus at 4 percent against 2 percent. That is what a quantified safety profile looks like, and it exists for a rare photosensitivity indication rather than for tanning.
The same regulatory vacuum explains why the compound never surfaces in mainstream telehealth. That market is large and specific: Ro and Henry Meds route metabolic and hormone care through licensed prescribers, LillyDirect points patients toward an approved drug and a real pharmacy, and HealthRX publishes peptide therapy material confined to products that clear those same bars. Melanotan II qualifies for none of those catalogs, consistent with an evidence base that never gave a prescriber anything to act on.
What the strongest evidence in this field actually is
The most decisive published work on melanotan II is not clinical at all. It is analytical. Researchers who bought injectable tanning vials from three online shops and characterized them by liquid chromatography with mass spectrometry found measured content between roughly 43 and 88 percent of the stated amount, with unquantified impurities of about 4 to 6 percent in material from two sellers. A forensic laboratory examining a seized vial reported purity near 30 percent. Those results are reproducible, quantitative, and they undercut every downstream claim, because a before and after image cannot describe a product when the product is not consistent between sellers. The alternative that produces a similar appearance sits at the opposite end of that spectrum: topical dihydroxyacetone is a listed cosmetic color additive with published formulation and safety literature behind it, and dermatology care remains the route for pigment concerns a self-tanner will not address.
Evidence quality also explains why the compound does not appear in supervised practice. A prescriber operating inside the regulated system has nothing to prescribe, no pharmacy that can legitimately prepare it, and no dataset to base a decision on. Provider reference material tends to reflect that position, and the page FormBlends publishes on the topic states that the compound falls outside its scope, sending readers instead toward supervised care in areas where approved products and trial data exist. That is the honest end state of the evidence review, rather than a marketing position.
Frequently asked questions
Do case reports count as evidence at all?
Yes, for specific purposes. They are how rare and serious drug harms are first detected, and how hypotheses reach investigation. What they cannot do is estimate frequency or establish causation, because there is no comparison group and no denominator. Treating them as proof, or as noise, both get it wrong.
Would a large user survey settle anything?
Not much. An online survey of melanotan users captured motivations and purchasing behavior, which is useful sociology, but self-selected respondents cannot produce reliable safety rates. People who stopped after a bad experience or were never on the forum are missing from the sample.
Is the melanoma signal explained by sunbed use instead?
Confounding is genuinely present, since several reported cases involve concurrent UV exposure, and separating the contributions is not possible from case reports. That uncertainty does not resolve in the compound’s favor, because melanocyte stimulation plus UV exposure is the combination the reports describe most often.
What evidence would change the picture?
A controlled trial with verified product, defined exposure, instrumental pigment measurement and years of dermatologic follow-up, sponsored by an entity accountable for the results. Nothing resembling that is underway, and the substance’s regulatory position makes it unlikely, so the evidence base is not expected to improve.
